Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

58.32 -2.77 (-4.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,693,932
Open 60.78
Bid (Size) 40.67 (2)
Ask (Size) 65.00 (6)
Prev. Close 61.09
Today's Range 56.02 - 61.16
52wk Range 30.58 - 70.00
Shares Outstanding 109,865,305
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Where Apellis Pharmaceuticals Stands With Analysts
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings: 
Via Benzinga
Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Stifel has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and raise its price target from $60.00 to $65.00. Shares of Apellis Pharmaceuticals are trading up 2.69% over the... 
Via Benzinga

Performance

YTD
+19.58%
+19.58%
1 Month
-1.67%
-1.67%
3 Month
+25.72%
+25.72%
6 Month
+21.25%
+21.25%
1 Year
+85.73%
+85.73%

More News

Read More
Moderna To $165? Plus This Analyst Cuts PT On FedEx
Via Benzinga
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday
Via Benzinga
Apellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two Years
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
Via Benzinga
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals
Via Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
Via Benzinga
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Climbs Over 500 Points as Upbeat Earnings Roll In
Via Talk Markets
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance
Via Benzinga
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why U.S. Stocks Are Trading Higher; Housing Starts Drop Further In June
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
Via Benzinga
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Via Investor's Business Daily
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Via Benzinga
Why Apellis Pharmaceuticals Stock Is Soaring
Via Benzinga
Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.